Clinical Trial Update: PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating a combination of a PD-1 antibody, chidamide, lenalidomide, and etoposide for relapsed or refractory NK/T cell lymphoma is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Etoposide (Etoposide)
• Lenalidomide (lenalidomide)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Mingzhi Zhang | Conditions: NK/T Cell Lymphoma | Phase 4 | Status: UNKNOWN